April 2024
1. JONES RJ, Crabb SJ, Linch M, Birtle AJ, et al
   Systemic anticancer therapy for urothelial carcinoma: UK oncologists' perspective.
   Br J Cancer. 2024;130:897-907.
   

   >> Share

   
   March 2024
2. OUYANG Y, Zhong W, Xu P, Wang B, et al
   Tumor-associated neutrophils suppress CD8(+) T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis.
   Br J Cancer. 2024;130:880-891.
   

   >> Share

   
   February 2024
3. ZHANG L, Zhang R, Jin D, Zhang T, et al
   Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer.
   Br J Cancer. 2024 Feb 8. doi: 10.1038/s41416-024-02598.
   

   >> Share

   
   
4. FONT A, Mellado B, Climent MA, Virizuela JA, et al
   Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
   Br J Cancer. 2024;130:434-441.
   

   >> Share

   
   January 2024
5. SU X, Jin K, Guo Q, Xu Z, et al
   Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer.
   Br J Cancer. 2024 Jan 11. doi: 10.1038/s41416-023-02572.
   

   >> Share

   
   December 2023
6. VIERGEVER BJ, Raats DAE, Geurts V, Mullenders J, et al
   Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.
   Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02494.
   

   >> Share

   
   September 2023
7. LIM EH, Franklin P, Trevenen ML, Nieuwenhuijsen M, et al
   Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia.
   Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411.
   

   >> Share

   
   August 2023
8. LU J, Lai J, Xiao K, Peng S, et al
   A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study.
   Br J Cancer. 2023 Aug 4. doi: 10.1038/s41416-023-02383.
   

   >> Share

   
   July 2023
9. SHALA NK, Stenehjem JS, Babigumira R, Liu FC, et al
   Exposure to benzene and other hydrocarbons and risk of bladder cancer among male offshore petroleum workers.
   Br J Cancer. 2023 Jul 18. doi: 10.1038/s41416-023-02357.
   

   >> Share

   
   June 2023
10. YAMAMOTO S, Kato M, Takeyama Y, Azuma Y, et al
    Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma.
    Br J Cancer. 2023;128:2197-2205.
    

    >> Share

    
    March 2023
11. VASDEV N
    Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients.
    Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02142.
    

    >> Share

    
    February 2023
12. TSAI YC, Wang TY, Hsu CL, Lin WC, et al
    Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling.
    Br J Cancer. 2023 Feb 21. doi: 10.1038/s41416-023-02195.
    

    >> Share

    
    January 2023
13. XU L, Zhong W, Li C, Hong P, et al
    The tumour-associated stroma correlates with poor clinical outcomes and immunoevasive contexture in patients with upper tract urothelial carcinoma: results from a multicenter real-world study (TSU-01 Study).
    Br J Cancer. 2023;128:310-320.
    

    >> Share

    
    November 2022
14. REN J, Yu H, Li W, Jin X, et al
    Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer.
    Br J Cancer. 2022 Nov 17. pii: 10.1038/s41416-022-02058.
    

    >> Share

    
    October 2022
15. MENGUAL L, Frantzi M, Mokou M, Ingelmo-Torres M, et al
    Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients.
    Br J Cancer. 2022 Oct 3. pii: 10.1038/s41416-022-01992.
    

    >> Share

    
    August 2022
16. LIU C, Liu Z, Jin K, Zeng H, et al
    Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01943.
    

    >> Share

    
    July 2022
17. TOMIYAMA E, Fujita K, Matsuzaki K, Narumi R, et al
    EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer.
    Br J Cancer. 2022 Jul 6. pii: 10.1038/s41416-022-01860.
    

    >> Share

    
    April 2022
18. ZHOU Z, Zhang Z, Chen H, Bao W, et al
    SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.
    Br J Cancer. 2022 Apr 28. pii: 10.1038/s41416-022-01794.
    

    >> Share

    
    
19. DE JONG JJ, Valderrama BP, Perera J, Juanpere N, et al
    Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis.
    Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01799.
    

    >> Share

    
    March 2022
20. LETT L, George M, Slater R, De Lacy Costello B, et al
    Investigation of urinary volatile organic compounds as novel diagnostic and surveillance biomarkers of bladder cancer.
    Br J Cancer. 2022 Mar 29. pii: 10.1038/s41416-022-01785.
    

    >> Share

    
    
21. NARII N, Sobue T, Zha L, Kitamura T, et al
    Vegetable and fruit intake and the risk of bladder cancer: Japan Public Health Center-based prospective study.
    Br J Cancer. 2022 Mar 3. pii: 10.1038/s41416-022-01739.
    

    >> Share

    
    February 2022
22. CHEN J, Rodopoulou S, Strak M, de Hoogh K, et al
    Long-term exposure to ambient air pollution and bladder cancer incidence in a pooled European cohort: the ELAPSE project.
    Br J Cancer. 2022 Feb 16. pii: 10.1038/s41416-022-01735.
    

    >> Share

    
    
23. JIN K, Yu Y, Zeng H, Liu Z, et al
    CD103(+)CD8(+) tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer.
    Br J Cancer. 2022 Feb 14. pii: 10.1038/s41416-022-01725.
    

    >> Share

    
    
24. SHOHDY KS, Villamar DM, Cao Y, Trieu J, et al
    Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
    Br J Cancer. 2022;126:430-439.
    

    >> Share

    
    January 2022
25. LIU Z, Zeng H, Jin K, Yu Y, et al
    TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Br J Cancer. 2022 Jan 17. pii: 10.1038/s41416-022-01703.
    

    >> Share

    
    November 2021
26. IKARASHI D, Kitano S, Tsuyukubo T, Takenouchi K, et al
    Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting.
    Br J Cancer. 2021 Nov 15. pii: 10.1038/s41416-021-01628.
    

    >> Share

    
    October 2021
27. ROSE TL, Weir WH, Mayhew GM, Shibata Y, et al
    Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
    Br J Cancer. 2021;125:1251-1260.
    

    >> Share

    
    September 2021
28. SILVERS CR, Messing EM, Miyamoto H, Lee YF, et al
    Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer.
    Br J Cancer. 2021 Sep 25. pii: 10.1038/s41416-021-01554.
    

    >> Share

    
    April 2021
29. KHAN MT, Irlam-Jones JJ, Pereira RR, Lane B, et al
    A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01326.
    

    >> Share

    
    March 2021
30. TEO MY, Al-Ahmadie H, Seier K, Tully C, et al
    Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
    Br J Cancer. 2021;124:1214-1221.
    

    >> Share

    
    February 2021
31. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    

    >> Share

    
    August 2020
32. REZENDE LFM, Lee DH, Keum N, Wu K, et al
    Resistance training and total and site-specific cancer risk: a prospective cohort study of 33,787 US men.
    Br J Cancer. 2020;123:666-672.
    

    >> Share

    
    July 2020
33. PATTARAWAT P, Hong T, Wallace S, Hu Y, et al
    Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.
    Br J Cancer. 2020;123:226-239.
    

    >> Share

    
    December 2019
34. BENGTSEN MB, Veres K, Norgaard M
    First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
    Br J Cancer. 2019 Dec 6. pii: 10.1038/s41416-019-0668.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share